Lithium (Orotate) 5 mg
Product analysis
Lithium (Orotate) 5 mg is aimed at mood support, with its lithium form and amount clearly stated. Effects from monitored prescription lithium treatment cannot be assumed for this supplement.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality91
The lithium compound is clearly identified as orotate. The precise NAC preparation is not disclosed, limiting a comparison of the complete formula.
Ingredient Transparency81
Both ingredient amounts are stated, making the main contents identifiable. Lithium orotate is named, while the precise NAC preparation is missing.
Value For Money60
The cost per lithium serving appears reasonable. That price comparison does not establish an effective mood-support serving.
Customer Satisfaction68
Customer ratings are favorable. The small number of ratings leaves a limited satisfaction picture and does not establish mood effects.
Product Focus81
The formula has a narrow mood-support aim, but a general mood benefit at this supplement exposure is not established. Findings from monitored prescription lithium treatment cannot be transferred to it.
- Format
Capsule - Container
- 180 Capsule(s)
- Per serving
- $0.26
- Customer rating
- 4.6 · 83 ratings
Goals
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Lithium (Lithium Orotate) | 5 mg | |
N-Acetyl L-Cysteine | 200 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability100
Lithium Compound Optimization
Dose, Safety & Label Transparency100
Elemental Disclosure Precision
Dosage Appropriateness
Value60
Cost Per Serving Efficiency
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
- GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
- A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
- A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.